Product Description
Mechanisms of Action: H1 Antagonist,Calcium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Denmark | Dominican Republic | Ecuador | Egypt | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Jordan | Korea | Lebanon | Luxembourg | Malaysia | Malta | Mexico | Netherlands | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Saudi Arabia | Singapore | Slovenia | South Africa | Spain | Sri Lanka | Switzerland | Taiwan | Turkey | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Intestinal Diseases|Liver Cirrhosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACTRN12616000437460 | P1 |
Completed |
Intestinal Diseases|Liver Cirrhosis |
2022-06-15 |